东亚药业(605177) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥254,966,058.04, representing a year-on-year increase of 34.45%[5] - The net profit attributable to shareholders decreased by 8.47% to ¥22,461,105.10 compared to the same period last year[5] - Basic earnings per share (EPS) was ¥0.20, down by 9.09% from the previous year[5] - The net profit for Q1 2022 was 22,461,105.10, a decrease of 8.5% compared to 24,540,005.70 in Q1 2021[23] - Operating profit for Q1 2022 was 28,111,108.02, down from 30,644,882.75 in the same period last year, reflecting a decline of 8.3%[26] - Total revenue from sales of goods and services in Q1 2022 was 164,651,123.39, an increase of 19.9% from 137,367,582.36 in Q1 2021[26] - The company reported a total comprehensive income of 22,461,105.10 for Q1 2022, which is a decrease of 8.5% from 24,540,005.70 in Q1 2021[23] - Basic and diluted earnings per share for Q1 2022 were both 0.20, down from 0.22 in Q1 2021[23] Cash Flow and Assets - The net cash flow from operating activities was negative at ¥-14,747,411.47, a decline of 131.47% year-on-year[5][10] - Cash and cash equivalents as of March 31, 2022, were RMB 497,876,603.38, down from RMB 556,101,874.98 at the end of 2021, representing a decrease of 10.4%[17] - The cash flow from operating activities in Q1 2022 was negative at -14,747,411.47, compared to a positive cash flow of 46,869,087.68 in Q1 2021[26] - The cash and cash equivalents at the end of Q1 2022 were 497,876,603.38, down from 682,797,022.76 at the end of Q1 2021[27] - The total cash outflow from investing activities in Q1 2022 was -35,703,896.75, compared to -288,867,107.27 in Q1 2021, indicating a significant reduction in cash outflow[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,271,868,148.48, an increase of 0.92% from the end of the previous year[6] - Total assets as of March 31, 2022, amounted to RMB 2,271,868,148.48, compared to RMB 2,251,076,133.47 at the end of 2021, indicating a growth of 0.9%[19] - Total liabilities as of March 31, 2022, were RMB 491,321,650.21, slightly down from RMB 492,990,740.30 at the end of 2021[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,023[12] - The largest shareholder, Chi Zhengming, holds 41.48% of the shares, totaling 47,116,769 shares[13] Operating Costs and Expenses - Total operating costs for Q1 2022 were RMB 228,080,537.00, up 41.5% from RMB 160,904,935.12 in Q1 2021[21] - Research and development expenses for Q1 2022 were 8,485,988.91, a decrease of 15.1% compared to 9,997,252.39 in Q1 2021[26] - The company incurred a financial expense of -3,544,370.85 in Q1 2022, an improvement from -6,212,055.12 in Q1 2021[26] Other Information - The company experienced a significant increase in sales revenue, which was the primary reason for the growth in operating income[10] - The company has not disclosed any new product developments or market expansion strategies in the provided documents[15] - There are no significant mergers or acquisitions reported during the quarter[15]